Lorem ipsum dolor sit amet, consectetur adipiscing elit

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Lorem ipsum

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

The unmet clinical need

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit
amet, consectetur ad
ipisicing elit, sed do
eiusmod tempor incididunt
ut labore et
dolore magna aliqua. Ut enim ad min
im veniam, quis nostrud exercitation ullamco laboris.

Latest press releases

First patients treated in Annexin’s Phase 2a study in diabetic retinopathy and RVO

Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy…

Latest press releases

Annexin Pharmaceuticals selected to present at the Eyecelerator conference and meets with the Medical Advisory Board in Orlando

Annexin Pharmaceuticals AB has been selected from “a record-breaking pool of applicants” to present at Eyecelerator, a meeting in connection with the annual AAO Congress (American Academy of Ophthalmology) 2025…

Latest press releases

Annexin appoints world-leading ophthalmology experts to Medical Advisory Board

Annexin Pharmaceuticals AB has appointed a Medical Advisory Board in Ophthalmology. The independent clinical experts in the Board will act as key advisors to the Annexin team advancing the clinical…

Latest press releases

Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO

Annexin Pharmaceuticals AB has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start a clinical Proof of Concept phase 2a study with the drug candidate…